Navigation Links
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Date:2/11/2013

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188.  

Brian M. Culley , Chief Executive Officer, said: "Consistent with our guidance from October 2011 and our commitment to FDA, we have initiated this study before the end of the first quarter.  We were pleased with the discussion we had with the Agency on the study protocol and our agreement on the supra-therapeutic dose." 

Santosh Vetticaden, Chief Medical Officer, said: "The FDA requires an assessment of cardiac repolarization for most new drugs having systemic bioavailability. This study will assess whether or not ANX-188 has an effect on QT prolongation. The study should complete dosing in the first quarter, and we expect to announce results in the second quarter of 2013."

The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers.  The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial.  Sixty subjects will be enrolled.  Each subject will receive each of four treatments (placebo, active control, ANX-188 therapeutic dose, ANX-188 supra-therapeutic dose) during each of the four treatment periods.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions.  The C
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Establishment of Regulatory Advisory Board
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
5. Applied Genetics Initiates Commercial Operation
6. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
10. Positive Clinical Study Results for BSPs HyperQ Technology
11. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... BellBrook Labs announced today that they ... powerful Orthogonal Pooled Screening (OPS) Platform developed and ... Lankenau Institute for Medical Research (LCGC) in Wynnewood, ... successful drug discovery outcomes using far more efficient ... available nowhere else, coupled to a state-of-the-art compound ...
(Date:4/16/2015)... Miami, FL (PRWEB) April 16, 2015 ... therapy cap distribution and physician network in Europe ... marketing company has appointed Fernando Bermúdez, former Business ... Director. , An industry veteran, Mr. Bermúdez’s professional ... by 75% in Spain, while also penetrating the ...
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
(Date:4/16/2015)... April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to ... in Charlottetown , PEI.  Bioenterprise has ... Island ADAPT Council for the commercialization of agricultural technologies ... working with PEI ADAPT.  They have been at the ... a decade," explains Dave Smardon , President & ...
Breaking Biology Technology:BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2
... with its goal of extending electronic government and ... how such a massive undertaking can take place ... sharing information and integrating systems has been clear ... , ,What has been missing is the organizational ...
... carefully established position as a nexus for research and development ... academic and other research institutions, according to a new report. ... This prediction comes from the Wisconsin Technology Council ... report, titled The Economic Value of Academic Research and Development ...
... Institutes of Health. Madison, Wis. ... Wednesday that it will receive a $1.26 million Phase II ... Health. , ,The funds will be used to help produce ... disorder that kills red blood cells. This results in a ...
Cached Biology Technology:State CIO wants to unify electronic government 2State CIO wants to unify electronic government 3State CIO wants to unify electronic government 4Economic report raises red flags on Wisconsin's future 2Economic report raises red flags on Wisconsin's future 3Mirus receives $1.26 million SBIR grant to combat anemia 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... assumed that if mercury is high and increasing in fish ... true of fish elsewhere in the Arctic. But a ... discovered that assumption is wrong in much of the continental ... a result of diverse atmospheric, geological, and biological conditions, "It ...
... developed a new vaccine that protects against lethal pneumonia ... drug-resistant strains like MRSA. The research team was ... in the UI Carver College of Medicine. The findings ... Infectious Disease . The new vaccine targets toxins ...
... , a sprawling shrub that grows on just a single ... in its family and genus. It is also one of ... 200 million years ago. Now, researchers from Indiana University, with ... Penn State University, and the Institute of Research for Development ...
Cached Biology News:Virginia Tech research overturns assumption about mercury in the Arctic 2Virginia Tech research overturns assumption about mercury in the Arctic 3Staph stoppers 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3
SAPK/JNK Antibody...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
... Signets FAST RED Chromogen ... chromogen,tablets and substrate buffer. FAST ... of alkaline phosphatase to produce ... noise. The ...
Biology Products: